H. M. van den Berg

发表

Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry‐based study

A. Hoes, P. Mol, C. J. Jonker, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study

C. Königs, E. Santagostino, H. M. van den Berg, 2020, Thrombosis and Haemostasis.

Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A.

C. Königs, R. Ljung, E. Santagostino, 2019, Blood.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

J. Oldenburg, R. Ljung, E. Santagostino, 2017, Thrombosis and Haemostasis.

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

G. Auerswald, R. Ljung, E. Santagostino, 2015, Thrombosis and Haemostasis.

Different impact of factor VIII products on inhibitor development?

H. M. van den Berg, 2016, Thrombosis Journal.

Factor VIII products and inhibitor development in severe hemophilia A.

R. Ljung, E. Santagostino, J. G. van der Bom, 2013, The New England journal of medicine.

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.

M. Margaglione, S. Cessie, S. le Cessie, 2012, Blood.

Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients

J. G. van der Bom, H. M. van den Berg, S. Gouw, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment

J. Voorberg, H. M. van den Berg, S. Gouw, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice

E. Santagostino, K. Fischer, J. G. van der Bom, 2008, Journal of thrombosis and haemostasis : JTH.

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

G. Auerswald, J. G. van der Bom, H. M. van den Berg, 2007, Blood.

Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

L. Mantovani, J. Astermark, H. M. van den Berg, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors

L. Mantovani, J. Astermark, H. M. van den Berg, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

NO PROTECTIVE EFFECT OF BREASTFEEDING ON INHIBITOR FORMATION IN SEVERE HEMOPHILIA

K. Fischer, J. G. van der Bom, H. M. van den Berg, 2005, Pediatric hematology and oncology.

Issues surrounding therapeutic choices for hemophilia patients.

H. M. van den Berg, 2004, Haematologica.

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.

F. Rosendaal, J. van der Meer, H. M. van den Berg, 1993, Blood.

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A

K. Fischer, J. G. van der Bom, H. M. van den Berg, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.

P. Lenting, C. Denis, H. M. van den Berg, 2008, Blood.

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

P. D. de Groot, P. Lenting, C. Denis, 2007, Blood.

Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients

H. M. van den Berg, E. Mauser-Bunschoten, H. Zaaijer, 1995, Journal of medical virology.

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders

A. Hoes, P. Mol, P. McGettigan, 2021, Drug Safety.

Validity of health status measurement with the Dutch Arthritis Impact Measurement Scale 2 in individuals with severe haemophilia

P. Helders, N. V. van Meeteren, H. M. van den Berg, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

The utility of the Dutch Arthritis Impact Measurement Scales 2 for assessing health status in individuals with haemophilia: a pilot study

P. Helders, N. V. van Meeteren, H. M. van den Berg, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

The Half-life of Infused Factor VIII Is Shorter in Hemophiliac Patients with Blood Group 0 than in those with Blood Group A

J. Sixma, H. M. van den Berg, E. Mauser-Bunschoten, 2000, Thrombosis and Haemostasis.

Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score

R. Engelbert, V. Blanchette, A. Abad, 2011, Arthritis care & research.

Phenotypic heterogeneity in severe hemophilia

P. D. de Groot, K. Fischer, H. M. van den Berg, 2007, Journal of thrombosis and haemostasis : JTH.

Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis

K. Fischer, H. M. van den Berg, K. van Dijk, 2007, Journal of thrombosis and haemostasis : JTH.

Assessment of incidence of inhibitors in patients with haemophilia

B. Psaty, N. Weiss, B. Psaty, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C infection and viremia in Dutch Hemophilia patients

H. Reesink, H. M. van den Berg, G. Roosendaal, 1995, Journal of medical virology.

Factor VIII‐specific memory B cells in patients with hemophilia A

J. Voorberg, K. Fijnvandraat, H. M. van den Berg, 2007, Journal of thrombosis and haemostasis : JTH.

Progression to AIDS in Relation to Clinical Factors and Clotting Product Consumption

Y. T. van der Schouw, H. M. van den Berg, G. Roosendaal, 1998, Vox Sanguinis.

A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A

D. Lewandowski, K. Fischer, B. van Hout, 2011, Haematologica.

Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C

R. Chamuleau, H. Reesink, M. Damen, 1996, Annals of Internal Medicine.

Safety and efficacy of a plasma‐derived monoclonal purified factor VIII concentrate during 10 years of follow‐up

K. Fischer, H. M. van den Berg, E. Mauser-Bunschoten, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Kinetics of factor VIII-von Willebrand factor association.

J. Sixma, H. M. van den Berg, J. Meijers, 1996, Blood.

Low-dose immune tolerance induction in hemophilia A patients with inhibitors.

H. M. van den Berg, G. Roosendaal, E. Mauser-Bunschoten, 1995, Blood.

Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide

J. Voorberg, H. M. van den Berg, E. Mauser-Bunschoten, 2002, British journal of haematology.

Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study.

J. Bijlsma, F. Lafeber, H. M. van den Berg, 2003, Rheumatology.

Blood-induced joint damage: a human in vitro study.

J. Bijlsma, F. Lafeber, H. M. van den Berg, 1999, Arthritis and rheumatism.

Drug Registries and Approval of Drugs: Promises, Placebo, or a Real Success?

A. Hoes, P. Mol, C. J. Jonker, 2018, Clinical therapeutics.

First‐year results of an expanded humanitarian aid programme for haemophilia in resource‐constrained countries

F. Peyvandi, H. M. van den Berg, G. Pierce, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A

M. Carcao, A. Rafowicz, K. Fischer, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors

H. M. van den Berg, D. Cross, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Age at first treatment and immune tolerance to factor VIII in severe hemophilia

K. Fischer, J. G. van der Bom, H. M. van den Berg, 2003, Thrombosis and Haemostasis.

Motor performance and disability in Dutch children with haemophilia: a comparison with their healthy peers

P. Helders, H. M. van den Berg, M. Schoenmakers, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization.

W. Mali, H. M. van den Berg, G. Roosendaal, 2005, Blood.

Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients

P. Lenting, C. Denis, K. Fischer, 2009, PloS one.

Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia

F. Beek, K. Fischer, J. G. van der Bom, 2001, British journal of haematology.

Blood-induced joint damage: a canine in vivo study.

J. Bijlsma, F. Lafeber, J. Tekoppele, 1999, Arthritis and rheumatism.

Association between joint bleeds and Pettersson scores in severe haemophilia.

D. Grobbee, K. Fischer, B. van Hout, 2002, Acta radiologica.

Iron deposits and catabolic properties of synovial tissue from patients with haemophilia.

J. Bijlsma, J. Bijlsma, F. Lafeber, 1998, The Journal of bone and joint surgery. British volume.

Cartilage damage as a result of hemarthrosis in a human in vitro model.

J. Bijlsma, F. Lafeber, H. M. van den Berg, 1997, The Journal of rheumatology.

Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy.

J. Bijlsma, H. M. van den Berg, G. Roosendaal, 2004, Arthritis and rheumatism.

Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage: an in vivo animal study.

J. Bijlsma, H. M. van den Berg, G. Roosendaal, 2003, Arthritis and rheumatism.

Articular cartilage is more susceptible to blood induced damage at young than at old age.

J. Bijlsma, F. Lafeber, J. Tekoppele, 2000, The Journal of rheumatology.

Blood-induced joint damage: a canine in vivo study.

J. Bijlsma, F. Lafeber, J. Tekoppele, 1999, Arthritis and rheumatism.

Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy

V. Blanchette, K. Fischer, H. M. van den Berg, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

IgG subclasses of anti‐FVIII antibodies during immune tolerance induction in patients with hemophilia A

J. Voorberg, G. Vidarsson, H. M. van den Berg, 2008, British journal of haematology.

K. Fischer, H. M. van den Berg, J. van der Bom, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Pathology of synovitis and hemophilic arthropathy

J. Bijlsma, F. Lafeber, H. M. van den Berg, 1999, Der Orthopäde.

WFH Guidelines for the Management of Hemophilia, 3rd edition

E. Santagostino, M. Carcao, B. Feldman, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

R. Ljung, K. Fischer, H. M. van den Berg, 2013, Blood.

A survey of adherence to haemophilia therapy in six European countries: results and recommendations

H. M. van den Berg, M. Richards, P. Moerloose, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature

D. Grobbee, K. Fischer, J. G. van der Bom, 2004, Thrombosis and Haemostasis.

Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome

D. Grobbee, C. Négrier, K. Fischer, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome

D. Grobbee, K. Fischer, J. G. van der Bom, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.

A. Bianchi, R. Ljung, M. Carcao, 2013, Blood.

Factor VIII half-life and clinical phenotype of severe hemophilia A.

D. Grobbee, P. D. de Groot, P. Lenting, 2005, Haematologica.

Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy

K. Fischer, H. M. van den Berg, G. Roosendaal, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Primary prophylaxis in children with severe haemophilia A and B—Implementation over the last 20 years as illustrated in real‐world data in the PedNet cohorts

R. Ljung, H. M. van den Berg, Marloes de Kovel, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies

K. Fischer, J. G. van der Bom, H. M. van den Berg, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylactic treatment for severe haemophilia: comparison of an intermediate‐dose to a high‐dose regimen

D. Grobbee, J. Astermark, D. Grobbee, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Dose and outcome of care in haemophilia – how do we define cost‐effectiveness?

A. Viswabandya, V. Mathews, K. Fischer, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Comparing outcomes of different treatment regimens for severe haemophilia

K. Fischer, J. Bom, H. M. van den Berg, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis for Severe Hemophilia: Experience from Europe and the United States

K. Fischer, H. M. van den Berg, H. Marijke van den Berg, M.D., Ph.D.,, 2003, Seminars in thrombosis and hemostasis.

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

J. Oldenburg, G. Auerswald, R. Ljung, 2013, Blood.

Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia.

D. Grobbee, F. Beek, K. Fischer, 2000, Thrombosis and haemostasis.

Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A

J. Voorberg, K. Fischer, H. M. van den Berg, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Product choice and haemophilia treatment in the Netherlands

H. M. van den Berg, G. Roosendaal, E. Mauser-Bunschoten, 2001, Haemophilia.

RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia

D. Grobbee, D. Grobbee, K. Fischer, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Association between joint bleeds and pettersson scores in severe haemophilia

D. Grobbee, K. Fischer, B. van Hout, 2002 .

Enhanced communication between care professionals and patients with hemophilia by using a web enabled electronic logbook.

H. M. van den Berg, G. Roosendaal, E. Drenth, 2004, Studies in health technology and informatics.

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study

C. Königs, R. Ljung, E. Santagostino, 2020, Haematologica.

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies

A. Weill, M. Skinner, S. Pipe, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Low-dose immune tolerance therapy: the van creveld model.

H. M. van den Berg, G. Roosendaal, E. Mauser-Bunschoten, 1996, Vox sanguinis.

Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources

H. M. van den Berg, A. Hilger, C. Keipert, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Assessment of Clotting Factor Concentrates—Pivotal Studies and Long-Term Requirements

F. Peyvandi, H. M. van den Berg, 2015, Seminars in Thrombosis & Hemostasis.

Clinical Course of Factor VIII Inhibitors Developed after Exposure to a Pasteurised Dutch Concentrate Compared to Classic Inhibitors in Hemophilia A

F. Rosendaal, H. M. van den Berg, G. Roosendaal, 1994, Thrombosis and Haemostasis.

In vivo recovery and safety of human factor VIII product AAFACT® in patients with haemophilia A

M. Peters, H. M. van den Berg, F. Leebeek, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

H. M. van den Berg, G. Roosendaal, E. Mauser-Bunschoten, 1998, Vox Sanguinis.

World bleeding disorders registry: The pilot study

A. Iorio, D. Lillicrap, H. M. van den Berg, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.

M. Hermus, R. Chamuleau, M. Damen, 2001, Scandinavian journal of gastroenterology.

Factor VIII products and inhibitors in severe hemophilia A.

J. G. van der Bom, H. M. van den Berg, S. Gouw, 2013, The New England journal of medicine.

Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch hemophilia patients in relation to transfusion history.

M. Damen, H. M. van den Berg, G. Roosendaal, 1998, Blood.

Registries supporting new drug applications

A. Hoes, P. Mol, H. M. van den Berg, 2017, Pharmacoepidemiology and drug safety.

Formation of Antibodies to Factor VIII in Patients with Hemophilia A Who Are Treated with Interferon for Chronic Hepatitis C

H. Reesink, M. Damen, H. M. van den Berg, 1996, Annals of Internal Medicine.